University of California, Irvine

Running trials

• Not yet recruiting

  Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2

  NCT07875790· Washington University School of Medicine· Source

• Not yet recruiting

  Self-administered Acupressure in Patients With Sickle Cell Disease

  NCT07875777· University of Cincinnati· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

  NCT07853807· Washington University School of Medicine· Source

• Not yet recruiting

  HOPE Intervention for Fitness

  NCT07114822· University of California, Irvine· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Recruiting

  ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

  NCT07021989· Phase 2· Michael Spinner, MD· Source

• Recruiting

  A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  NCT07570862· Phase 2· Fate Therapeutics· Source

• Recruiting

  Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  NCT07504458· Phase 3· Quetzal Therapeutics· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

  NCT07354724· Phase 1· Denali Therapeutics Inc.· Source

• Recruiting

  A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  NCT07265674· Phase 3· J-Pharma Co., Ltd.· Source

• Recruiting

  Collaboration for Down Syndrome Progress (CDP)

  NCT07625579· RTI International· Source

• Recruiting

  Descartes-08 in Autoantibody Myositis

  NCT07391605· Phase 2· Cartesian Therapeutics· Source

• Recruiting

  Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

  NCT07451613· Phase 1/2· Leslie Thompson· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

  NCT07140016· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

  NCT07029828· Phase 3· Pfizer· Source

• Recruiting

  Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

  NCT06955169· Phase 2· RTOG Foundation, Inc.· Source

• Recruiting

  Telerehabilitation In The Home After Stroke

  NCT06682429· University of California, Los Angeles· Source

• Recruiting

  Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke

  NCT07042152· University of California, Irvine· Source

• Recruiting

  Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

  NCT06898515· Reprieve Cardiovascular, Inc· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

  NCT06970847· Phase 3· Clarity Pharmaceuticals Ltd· Source

• Recruiting

  A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

  NCT06909214· Phase 4· argenx· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Recruiting

  Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  NCT06810544· Phase 1/2· Tango Therapeutics, Inc.· Source

• Recruiting

  Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

  NCT06783751· University of California, Irvine· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858878· Phase 3· Amgen· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Youth Nominated Support Team

  NCT05558332· University of California, Irvine· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Recruiting

  RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

  NCT06359041· Phase 1/2· Cabaletta Bio· Source

• Active, not recruiting

  VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

  NCT06249165· Phase 4· Duke University· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Recruiting

  The Effects of Energy Healing in Fibromyalgia

  NCT06552728· University of California, Irvine· Source

• Recruiting

  Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

  NCT06526858· DeepQure Inc.· Source

Showing 50 of 164.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Acute myeloid leukaemia4 recruiting
• Alopecia areata4 recruiting
• Dermatomyositis and polymyositis (myositis)4 recruiting
• Obesity4 recruiting
• Sickle cell disease4 recruiting
• Stroke4 recruiting
• Type 2 diabetes4 recruiting
• Alzheimer disease3 recruiting
• Epilepsy3 recruiting
• Frontotemporal dementia3 recruiting
• Heart failure3 recruiting
• Lupus (SLE)3 recruiting
• Myasthenia gravis3 recruiting
• Parkinson disease3 recruiting
• ALS (motor neurone disease)2 recruiting
• Bladder cancer2 recruiting
• Chronic kidney disease2 recruiting
• Gastric and oesophageal cancer2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Melanoma2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Pompe disease2 recruiting
• Prostate cancer2 recruiting
• Schizophrenia2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic aneurysm1 recruiting
• Autism1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Down syndrome1 recruiting
• Fibromyalgia1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Hypothyroidism1 recruiting
• IgA nephropathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Macular degeneration1 recruiting
• Meningioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Relaxation Music for Chronic Pain

  NCT06993272· University of California, Irvine· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

  NCT06524739· Phase 3· CSL Behring· Source

• Completed

  EchoTip AcuCore Post-Market Clinical Study

  NCT06358001· Cook Research Incorporated· Source

• Completed

  Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

  NCT06235099· Phase 3· Curium US LLC· Source

• Recruiting

  A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

  NCT06146257· Phase 1· GluBio Therapeutics Inc.· Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Phase 1· Ikena Oncology· Source

• Completed

  A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

  NCT06088199· Phase 3· Amgen· Source

• Completed

  A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

  NCT06013969· Phase 4· LEO Pharma· Source

• Completed

  Comparing Different Rehabilitation Exercise Strategies for Improving Arm Recovery After Stroke

  NCT05880940· University of California, Irvine· Source

• Completed

  Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

  NCT05971381· Avita Medical· Source

• Terminated

  RITUAL Ultivision AI CADe Randomized Controlled Trial

  NCT05732233· Satisfai Health, Inc.· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  NCT05317078· Phase 1· Amgen· Source

• Completed

  A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

  NCT05517603· Phase 1/2· AnnJi Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Amgen· Source

• Terminated

  A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

  NCT05576077· Phase 1· Turnstone Biologics, Corp.· Source

• Completed

  Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

  NCT05451212· Phase 1· Cabaletta Bio· Source

• Completed

  Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism

  NCT05568927· University of California, San Diego· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

  NCT05699460· AskBio Inc· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source

• Completed

  Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

  NCT05174312· Reprieve Cardiovascular, Inc· Source

• Completed

  SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

  NCT04417699· Phase 2· Providence Health & Services· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Amgen· Source

• Completed

  Defining Endpoints in Becker Muscular Dystrophy

  NCT05257473· Virginia Commonwealth University· Source

• Terminated

  Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT05237284· Phase 2· Sanofi· Source

• Terminated

  A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

  NCT05267470· Phase 1· Amgen· Source

• Completed

  Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

  NCT05232929· Phase 4· Genentech, Inc.· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

  NCT05039177· Phase 1/2· Erasca, Inc.· Source

• Completed

  Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

  NCT04683848· Phase 2· Tanabe Pharma America, Inc.· Source

• Terminated

  Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

  NCT04506086· Phase 4· Amgen· Source

• Completed

  Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

  NCT04635384· CareDx· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Bayer· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Completed

  A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

  NCT04752215· Phase 1· Boehringer Ingelheim· Source

• Recruiting

  A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT04830137· Phase 1· Nurix Therapeutics, Inc.· Source

• Completed

  Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

  NCT04802733· Phase 1· BlueRock Therapeutics· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Merus B.V.· Source

• Completed

  Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT04658472· Phase 2· Bioverativ, a Sanofi company· Source

• Completed

  LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

  NCT04790344· Boston Scientific Corporation· Source

• Completed

  Exploring Outcomes and Characteristics of Myasthenia Gravis 2

  NCT06002945· Yale University· Source

• Completed

  Evaluation of AMG 714 for Vitiligo

  NCT04338581· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

  NCT04387461· Phase 2· CG Oncology, Inc.· Source

• Withdrawn

  Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT04607772· Phase 1/2· Karyopharm Therapeutics Inc· Source

Showing 50 of 81.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease323 works · 8 trials
• Stroke135 works · 7 trials
• Lung cancer102 works · 26 trials
• Down syndrome71 works · 2 trials
• Prostate cancer62 works · 8 trials
• Tuberculosis52 works · 0 trials
• Schizophrenia50 works · 4 trials
• Melanoma43 works · 6 trials
• Ovarian cancer35 works · 2 trials
• Depression34 works · 0 trials
• Migraine25 works · 0 trials
• Myasthenia gravis25 works · 11 trials
• Glaucoma24 works · 0 trials
• Hearing loss21 works · 0 trials
• Sickle cell disease20 works · 8 trials
• Spinal cord injury19 works · 1 trial
• ALS (motor neurone disease)19 works · 6 trials
• Obstructive sleep apnoea19 works · 0 trials
• Chronic lymphocytic leukaemia19 works · 3 trials
• Alopecia areata18 works · 8 trials
• Macular degeneration17 works · 1 trial
• Pompe disease15 works · 5 trials
• Childhood cancers15 works · 3 trials
• Neuroendocrine tumours15 works · 1 trial
• Hodgkin lymphoma14 works · 2 trials
• Congenital heart disease13 works · 0 trials
• Frontotemporal dementia11 works · 4 trials
• Hydrocephalus10 works · 0 trials
• Huntington's disease9 works · 1 trial
• Vitiligo8 works · 5 trials